IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies ...

维生素 A 的主要活性代谢产物维甲酸（Retinoic Acid，RA），在 T 细胞亚群的分化和抗肿瘤免疫中有着重要作用。但此前，人们对其在缓解 γδ T 细胞免疫耗竭、促进抗肿瘤免疫方面的研究还相对较少。为了探索其中的奥秘，来自暨南大学附属第一医院等机构的研究人员开展了一系列研究，相关成果发表在《Cell Communication and Signaling》杂志上。

结核病（TB）仍是全球重大健康问题，现有疫苗卡介苗（BCG）对成人肺结核预防效果不佳。研究人员开展 MTBVAC 候选疫苗早期免疫应答研究。结果显示，MTBVAC 激活了 CD4 和 γδ T 细胞等，该研究为疫苗评估提供依据，助力 TB 防控。

We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis and low IL-6 secretion, representing a powerful modality with the potential to overcome the ...

The first candidate from this platform, INB-619, targets CD19, effectively eradicating B cells and providing sustained depletion in preclinical models while expanding both major γδ T cell subsets.

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. In preclinical models, INB-619 ...

has unveiled INB-600, its next-generation γδ T-cell-based T-cell engager (TCE) platform designed to address one of the shortcomings of current existing γδ TCEs, specifically insufficient numbers of γδ ...

INB-600 γδ T Cell Engager (TCE) Platform INB-619 is considered a next-generation γδ TCE targeting CD19 which eradicates B ...